← Search

Omics · study · 2026

Human CD14+ monocytes from volunteers before and after a 3 hours, 24 hours and 120 hours-period of methotrexate intake. METOMAC trial

Listed in NCBI GEO

Arthritis patients receive a weekly low-dose of Methotrexate (MTX) as a first-line disease modifying anti-rheumatic drug.

Description

Following low-dose administration, MTX typically reaches peak plasma concentrations after 1-2 hours, and almost completely disappears from the circulation by 24 hours. However, the kinetics of the anti-inflammatory action of MTX in monocytes after the initial dose is unknown.To address this issue, we carried out a phase I clinical trial (METOMAC) in which peripheral blood from 6 healthy donors receiving a single dose of MTX was analyzed at distinct time points after drug intake (3 hours, 24 hours, 120 hours).

RNA-seq on monocytes isolated at the distinct timepoints was determined.

Links

Topics

From keywords
Life Sciences
Inferred from text
Disease 75% · RNA sequencing 65%
Provenance · 1 source records, 9 field assertions
SourceKeyLast seenRaw
NCBI GEOGSE28910114 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[disease].local:disease:diseaseenrichment · NCBI GEOkeyword-concept-rules@1.0.0title+description (75%)
concepts[field].local:field:life-sciencesmapping · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencingsource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[modality].local:modality:rna-seqenrichment · NCBI GEOkeyword-concept-rules@1.0.0title+description (65%)
concepts[organism].NCBITaxon:9606source · NCBI GEOconnector:ncbi_geo@1.0.0/taxon
descriptionsource · NCBI GEOconnector:ncbi_geo@1.0.0/summary
publication_datesource · NCBI GEOconnector:ncbi_geo@1.0.0
titlesource · NCBI GEOconnector:ncbi_geo@1.0.0/title